Linda Wicker

10PUBLICATIONS
57CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene expression (incl. microarray and other genome-wide approaches)AutoimmunityGene mapping
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 22, 2024
The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults.

M Loredana Marcovecchio, A Emile J Hendriks, Carl Delfin

|Apr 12, 2023
Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells.

Akimichi Inaba, Zewen Kelvin Tuong, Tian X Zhao

|Nov 28, 2022
Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes.

Jia-Yuan Zhang, Fiona Hamey, Dominik Trzupek

|Oct 15, 2021
Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73.

Lorna B Jarvis, Daniel B Rainbow, Valerie Coppard

|Jun 15, 2021
Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes.

Catherine C Robertson, Jamie R J Inshaw, Suna Onengut-Gumuscu

|May 14, 2020
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial.

M Loredana Marcovecchio, Linda S Wicker, David B Dunger

Pageof 2